文献速递消化道肿瘤放疗姑息放疗与转移瘤

PRIME-RT:度伐利尤单抗联合延长新辅助方案治疗直肠癌的随机II期试验方案

Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).
PubMed 文献 · Radiat Oncol · 2021-08-26

PRIME-RT是一项多中心、开放标签、随机II期试验,纳入新诊断局部晚期直肠癌(LARC)患者,随机接受短程放疗(25 Gy/5次)或长程放化疗(50 Gy/25次联合卡培他滨)联合度伐利尤单抗及FOLFOX方案。主要终点为各臂完全缓解率,次要终点包括治疗依从性、毒性、安全性、复发、永久性造口比例和生存。试验计划招募至多42例LARC患者,并先行至少6例的安全性导入。

要点

  • 探索免疫治疗加入LARC新辅助放化疗能否提高完全缓解率和无造口生存。
  • 短程放疗组:25 Gy/5次联合度伐利尤单抗序贯FOLFOX+度伐利尤单抗。
  • 长程放化疗组:50 Gy/25次联合卡培他滨序贯度伐利尤单抗+FOLFOX。

核心结论

  • PRIME-RT将探索在LARC新辅助放化疗中加入度伐利尤单抗能否改善肿瘤微环境以提高完全缓解率和无造口生存。

研究设计与样本

  • 多中心、开放标签、随机II期试验,纳入新诊断LARC患者,随机分配至短程放疗联合度伐利尤单抗序贯FOLFOX+度伐利尤单抗组或长程放化疗联合度伐利尤单抗序贯FOLFOX+度伐利尤单抗组。
  • 短程放疗方案为25 Gy分5次一周内完成,度伐利尤单抗1500 mg静脉每4周一次,FOLFOX为每2周静脉给药(奥沙利铂85 mg/m2、亚叶酸350 mg、5-FU 400 mg/m2推注后2400 mg/m2输注46-48小时)。
  • 长程放化疗方案为原发肿瘤50 Gy分25次五周内完成,同期口服卡培他滨825 mg/m2每日两次于放疗日,联合度伐利尤单抗序贯FOLFOX和度伐利尤单抗。
  • 试验计划招募至多42例LARC患者,并于主试验前进行至少6例LARC或转移性疾病患者的安全性导入。
  • 主要终点为各臂完全缓解率,次要终点包括治疗依从性、毒性、安全性、总体复发、永久性造口比例和生存。

关键数值与推荐

  • 短程放疗:25 Gy分5次一周内完成。
  • 长程放化疗:原发肿瘤50 Gy分25次五周内完成,同期卡培他滨825 mg/m2每日两次于放疗日。
  • 度伐利尤单抗1500 mg静脉每4周一次。
  • FOLFOX:奥沙利铂85 mg/m2、亚叶酸350 mg、5-FU 400 mg/m2推注后2400 mg/m2输注46-48小时,每2周一次。
  • 主要终点为各臂完全缓解率;计划招募至多42例LARC患者,安全性导入至少6例。

临床怎么用

  • 该试验为LARC新辅助治疗中联合免疫治疗的前瞻性随机研究,结果可能影响未来完全缓解率和器官保留策略。
  • 试验包含治疗前、中、后生物标本采集,以探索治疗反应的分子和免疫因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advances in multi-modality treatment of locally advanced rectal cancer (LARC) have resulted in low local recurrence rates, but around 30% of patients will still die from distant metastatic disease. In parallel, there is increasing recognition that with radiotherapy and systemic treatment, some patients achieve a complete response and may avoid surgical resection, including in many cases, the need for a permanent stoma. Extended neoadjuvant regimes have emerged to address these concerns. The inclusion of immunotherapy in the neoadjuvant setting has the potential to further enhance this strategy by priming the local immune microenvironment and engaging the systemic immune response. METHODS: PRIME-RT is a multi-centre, open label, phase II, randomised trial for patients with newly diagnosed LARC. Eligible patients will be randomised to receive either: short course radiotherapy (25 Gray in 5 fractions over one week) with concomitant durvalumab (1500 mg administered intravenously every 4 weeks), followed by FOLFOX (85 mg/m2 oxaliplatin, 350 mg folinic acid and 400 mg/m2 bolus 5-fluorouracil (5-FU) given on day 1 followed by 2400 mg/m2 5-FU infusion over 46-48 h, all administered intravenously every 2 weeks), and durvalumab, or long course chemoradiotherapy (50 Gray to primary tumour in 25 fractions over 5 weeks with concomitant oral capecitabine 825 mg/m2 twice per day on days of radiotherapy) with durvalumab followed by FOLFOX and durvalumab. The primary endpoint is complete response rate in each arm. Secondary endpoints include treatment compliance, toxicity, safety, overall recurrence, proportion of patients with a permanent stoma, and survival. The study is translationally rich with collection of bio-specimens prior to, during, and following treatment in order to understand the molecular and immunological factors underpinning treatment response. The trial opened and the first patient was recruited in January 2021. The main trial will recruit up to 42 patients with LARC and commence after completion of a safety run-in that will recruit at least six patients with LARC or metastatic disease. DISCUSSION: PRIME-RT will explore if adding immunotherapy to neoadjuvant radiotherapy and chemotherapy for patients with LARC can prime the tumour microenvironment to improve complete response rates and stoma free survival. Sequential biopsies are a key component within the trial design that will provide new knowledge on how the tumour microenvironment changes at different time-points in response to multi-modality treatment. This expectation is that the trial will provide information to test this treatment within a large phase clinical trial. Trial registration Clinicaltrials.gov NCT04621370 (Registered 9th Nov 2020) EudraCT number 2019-001471-36 (Registered 6th Nov 2020).

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hanna CR, O'Cathail SM, Graham JS, et al. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiat Oncol. 2021. PMID: 34446053. doi:10.1186/s13014-021-01888-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。